行情

CASI

CASI

CASI制药
NASDAQ

实时行情|Nasdaq Last Sale

2.080
-0.160
-7.14%
盘后: 2.200 +0.12 +5.77% 18:15 03/27 EDT
开盘
2.200
昨收
2.240
最高
2.200
最低
2.000
成交量
14.16万
成交额
--
52周最高
3.820
52周最低
1.150
市值
2.06亿
市盈率(TTM)
-4.3369
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CASI价格均价为3.500,最高价位3.500,最低价为3.500。

EPS

CASI 新闻

更多
  • Insider Buying: The CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Chairman & CEO Just Bought US$1.1m Worth Of Shares
  • Simply Wall St. · 3小时前
  • Daily Insider Ratings Round Up 3/19/20
  • Seeking Alpha - Article · 03/20 20:34
  • CASI Pharmaceuticals EPS misses by $0.07, misses on revenue
  • seekingalpha · 03/16 16:07
  • CASI Pharmaceuticals Announces Full Year 2019 Financial Results
  • PR Newswire · 03/16 12:00

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

CASI 简况

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
展开

微牛提供CASI Pharmaceuticals Inc(NASDAQ-CASI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CASI股票新闻,以帮助您做出投资决策。